Cidara Therapeutics Inc (CDTX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8114)
◆英語タイトル:Cidara Therapeutics Inc (CDTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8114
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:51
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company’s pipeline products include novel echinocandin CD101 IV, for the treatment of systemic candida infections; CD201, a bispecific antimicrobial immunotherapy that is being developed for multi-drug resistant bacterial infections, and others. The company develops cloudbreak, an immunotherapy platform, which helps to create compounds that direct a patient’s immune cells to strike and kill pathogens, which cause infectious diseases. Cidara is headquartered in San Diego, California, the US.

Cidara Therapeutics Inc (CDTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Cidara Therapeutics Acquires Intellectual Property for CD101 from Seachaid Pharma 11
Venture Financing 12
Cidara Therapeutics Raises USD42 Million in Series B Financing 12
Cidara Therapeutics Raises USD32 Million in Series A Venture Financing 14
K2 Therapeutics Raises USD30 Million in Venture Financing 16
K2 Therapeutics Raises USD6 Million in Venture Financing 17
Partnerships 18
Veristat Enters into Partnership with Cidara Therapeutics 18
Equity Offering 19
Cidara Therapeutics Plans to Raise up to USD68.7 Million in Public Offering of shares 19
Cidara Therapeutics to Raise USD50 Million in First Tranche Private Placement of Shares 20
Cidara Therapeutics Prices Private Placement of Shares for USD20 Million 22
Cidara Therapeutics Raises USD27.8 Million in Public Offering of Shares 23
Cidara Therapeutics Raises USD76.8 Million in Initial Public Offering of Shares 25
Cidara Therapeutics Inc – Key Competitors 27
Cidara Therapeutics Inc – Key Employees 28
Cidara Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 08, 2018: Cidara provides corporate update and reports second quarter 2018 financial results 30
May 10, 2018: Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results 31
Feb 27, 2018: Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results 32
Nov 08, 2017: Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results 33
Aug 09, 2017: Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results 35
May 10, 2017: Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results 36
Mar 15, 2017: Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 37
Corporate Communications 38
Sep 12, 2018: Cidara Therapeutics names David Gollaher as bard director 38
Mar 01, 2018: Cidara Appoints Chrysa Mineo As Independent Director 39
Government and Public Interest 40
Sep 12, 2018: Celldom Awarded Phase II SBIR Grant to Advance Next Generation, High Throughput Single Cell Analysis Platform[Newswire : Healthcare-BW] 40
Product News 41
08/01/2017: Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC) 41
04/25/2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer 42
04/17/2017: Cidara Therapeutics to Present Data on Cloudbreak Antibacterial Immunotherapy CD201 at ECCMID and SID Annual Meetings 43
04/17/2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings 44
03/30/2017: Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First Cloudbreak Antibiotic Immunotherapy 46
Clinical Trials 47
Sep 25, 2017: Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting 47
May 30, 2017: Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association 48
Feb 21, 2017: Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC 49
Jan 04, 2017: Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cidara Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cidara Therapeutics Acquires Intellectual Property for CD101 from Seachaid Pharma 11
Cidara Therapeutics Raises USD42 Million in Series B Financing 12
Cidara Therapeutics Raises USD32 Million in Series A Venture Financing 14
K2 Therapeutics Raises USD30 Million in Venture Financing 16
K2 Therapeutics Raises USD6 Million in Venture Financing 17
Veristat Enters into Partnership with Cidara Therapeutics 18
Cidara Therapeutics Plans to Raise up to USD68.7 Million in Public Offering of shares 19
Cidara Therapeutics to Raise USD50 Million in First Tranche Private Placement of Shares 20
Cidara Therapeutics Prices Private Placement of Shares for USD20 Million 22
Cidara Therapeutics Raises USD27.8 Million in Public Offering of Shares 23
Cidara Therapeutics Raises USD76.8 Million in Initial Public Offering of Shares 25
Cidara Therapeutics Inc, Key Competitors 27
Cidara Therapeutics Inc, Key Employees 28
Cidara Therapeutics Inc, Subsidiaries 29

List of Figures
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Cidara Therapeutics Inc (CDTX):製薬・医療:M&Aディール及び事業提携情報(Cidara Therapeutics Inc (CDTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆